WALTHAM, MA – March 16, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that Kenneth S. Kornman, DDS, Ph.D., Chief Executive Officer of Interleukin Genetics, has presented at the following recent conferences:
- National Health Policy Conference, sponsored by America’s Health Insurance Plans (AHIP) Dental Summit, which took place on Tuesday, March 10, 2015, in Washington, DC. Kornman’s presentation, titled “The Medical-Dental Connections,” covered the effects of moderate to severe periodontitis on whole body inflammation and its consequences, including certain diseases of aging such as cardiovascular disease.
- Polish Society of Periodontology’s Spring Seminar, which took place on Friday, March 13, 2015, in Warsaw, Poland. Dr. Kornman’s presentation, titled “The Role of Inflammation in Periodontal Disease and other Chronic Diseases,” provided an overview of the role of periodontitis on whole body inflammation and the role of several risk factors, including smoking, diabetes, and IL-1 gene variations, in amplifying inflammation in the body. Dr. Kornman also addressed inflammation control and the future of healthcare.
“Periodontitis is a validated risk factor for a number of chronic diseases of aging, including coronary artery disease, stroke, rheumatoid arthritis and Type 2 diabetes,” stated Dr. Kornman. “Preventing periodontitis through professional cleanings and improved oral hygiene and treating periodontitis and its resulting inflammation have the potential to reduce the risk of multiple chronic diseases. Large studies have shown that treating periodontitis reduces the cost of managing several chronic diseases.”
Periodontitis is a chronic inflammatory disease initiated by specific bacteria that activate host mechanisms destroying the bone and connective tissues that support the teeth. Between 8% and 13% of the worldwide adult population exhibit severe generalized periodontitis, with many more having clinical signs of mild to moderate disease. Individuals who have a history of periodontitis and have been appropriately treated require more preventive care to maintain health. Although bacteria cause the disease, a small number of risk factors, including smoking, diabetes, IL-1 gene variations, obesity, stress, osteoporosis, and other inflammatory diseases have been associated with increased severity of periodontitis. Current treatments to prevent gum disease include good oral hygiene and professional dental cleanings on a regular basis depending on the needs of the patient. Data from the “Patient Stratification for Preventive Dental Care” study (Giannobile et al., June 2013) indicate that individuals with certain risk factors, including IL-1 gene variations, benefit significantly from cleanings twice annually, and patients with multiple risk factors appeared to require more than two cleanings annually to maintain health. The Company believes risk stratification of patients without a history of periodontitis may optimize preventative dental care to improve outcomes.
About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health related conditions. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics’ lead products include its proprietary PerioPredict® genetic risk panel for periodontal disease and tooth loss susceptibility available through dentists, and the Inherent Health® Weight Management Genetic Test that identifies the most effective diet program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA, and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Amendments (CLIA). For more information, please visit 126.96.36.199.
Certain statements contained herein are “forward-looking” statements. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company’s annual report on Form 10-K for the year ended December 31, 2013, and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.
Interleukin Genetics Contacts:
Matthew Haines/Susie Kim